Literature DB >> 12642874

Requirement of the coiled-coil domains of p92(c-Fes) for nuclear localization in myeloid cells upon induction of differentiation.

Enrico Tagliafico1, Michela Siena, Tommaso Zanocco-Marani, Rossella Manfredini, Elena Tenedini, Monica Montanari, Alexis Grande, Sergio Ferrari.   

Abstract

The nonreceptor tyrosine kinase Fes is implicated in myeloid cells differentiation. It has been observed that its localization can be cytoplasmic, perinuclear, or nuclear. To further characterize this point, we studied Fes subcellular localization in myeloid cell lines (HL60 and K562) and in COS1 cells. Fes was observed in both the nucleus and the cytoplasm of HL60, K562 cells overexpressing Fes and only in the cytoplasm of COS1 cells, suggesting that nuclear localization is cell context dependent. Moreover, in myeloid cells, the treatment with differentiation-inducing agents such as retinoic acid, phorbol esters and vitamin D, is followed by an increase of the oligomeric form of Fes in the nucleus. In fact, oligomerization seems to be necessary for translocation to occur, since Fes mutants missing the coiled-coil domains are not able to form oligomers and fail to localize in the nucleus. The active form of Fes is tyrosine phosphorylated; however, phosphorylation is not required for Fes to localize in the nucleus, since tyrosine kinase inhibitors do not block the translocation process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642874     DOI: 10.1038/sj.onc.1206279

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner, substrate and activator of the c-Fes protein tyrosine kinase.

Authors:  Frank J Delfino; Jonathan M Shaffer; Thomas E Smithgall
Journal:  Biochem J       Date:  2006-10-01       Impact factor: 3.857

2.  Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake; Thomas E Smithgall
Journal:  Int J Oncol       Date:  2009-01       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.